newsfilter
← Latest News
GlobeNewswire·

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month